Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

nts who discontinued study therapy in ETV-027, and subsequently restarted treatment in rollover study ETV-901, with a greater than 60 day gap between end of treatment in study ETV-027 and start of treatment in study ETV-901.

    -- ETV-027 compared 0.5 mg of BARACLUDE vs. 100 mg of lamivudine in
nucleoside-naive chronic HBeAg-negative chronic hepatitis B patients.
-- Rollover study ETV-901 was established as an open-label, follow-up
protocol for patients in phase II and III studies of BARACLUDE.
-- Due to ongoing blinding of study ETV-027, most patients retreated in
ETV-901 initially received a combination of 1 mg of BARACLUDE plus 100
mg of lamivudine, and were subsequently switched to 1 mg of BARACLUDE

The analysis cohort was defined regardless of treatment response at the end of dosing in study ETV-027, and independent of virologic or ALT measurements at the start of dosing in study ETV-901. During off-treatment follow-up, the majority of patients had recurrent levels of hepatitis B virus in the blood (viremia) and increases in ALT.

    Data Results
At the end of dosing for study ETV-027:
-- 94 percent (n=93/99) of the re-treatment cohort had undetectable viral
-- 78 percent (n=77/99) had ALT normalization
At entry into ETV-901:
-- Four percent (n=4/99) of patients had undetectable viral load
-- Eight percent (n=8/97) of patients had ALT normalization
Following re-treatment in study ETV-901:
-- 93 percent (n=82/88) of patients had undetectable viral load (HBV DNA
<300 copies/mL) by week 48 of re-treatment with BARACLUDE
-- 83 percent (n=79/95) of patients had ALT normalization (ALT less than
or equal to 1 times the upper limit of normal) by week 48 of re-
treatment BARACLUDE
Adverse events in study ETV-027/901 re-treatment cohort:
-- 67 percent (n=66/99) of patients experienced an adverse event. The most
common adverse events occurring in greater than ten percent of patients
were abdominal pain, fa

Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... Companies, Inc. (ICBU) has repositioned itself as a holding company ... foothold in the hydroponic, hemp and medical marijuana sectors. By ... the sector, and recently partnering with the Chippewa Tribe Nation ... marijuana, iMD is committing to bring its vision to the ...
(Date:1/23/2015)... Blood America, Inc. ( ) (OTC Bulletin Board: ... Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange ... shareholders detailing why a "YES" vote to increase the number ... As we reflect upon the 2014 fiscal year that ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... 2011 /PRNewswire-Asia/ -- Pharmaceutical company Hatchtech Pty Ltd has ... study to confirm the efficacy of its novel head ... is evaluating the efficacy, safety and tolerability of two ... to vehicle. The trial consists of treating 132 healthy ...
... Aug. 31, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... appointed Helen Torley, M.B. Ch. B., M.R.C.P.,  as Executive ... Dr. Torley will report to N. Anthony Coles, M.D., ... for all commercial activities related to Nexavar and the ...
Cached Medicine Technology:Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 2Hatchtech Completes Treatment Phase of 2b Clinical Trial of New-Generation Head Lice Treatment Deovo™ 3Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 2Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 3
(Date:1/22/2015)... January 22, 2015 Woodloch Pines, an ... been selected by TripAdvisor as the number one best large ... best in the world for their annual Travelers’ Choice Awards. ... community . The website is home to millions of unbiased ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... Juvent Sports ( ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: . , Every business who ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... full, study suggests , , MONDAY, June 16 (HealthDay News) -- ... sweeteners may help you feel fuller faster and decrease the ... this may be a new way to help people lose ... can stimulate the sense of taste -- included 2,436 overweight ...
... La.The first patient scans from a custom-built scanner ... (CT) technologies indicate that these scans could significantly ... more targeted treatment options, according to researchers at ... designed to help physicians determine stages of breast ...
... NEW ORLEANS, La.A new study, presented at the ... pre-target the treatment of cancer cellsbringing personalized medicine ... By combining new molecular imaging techniques with targeted ... treatment that can increase the effectiveness of therapies ...
... tomography (PET) and computed tomography (CT) scanning of ... can enable physicians to determine whether the cancer ... to perform surgery, according to researchers at the ... surgeries could be reduced, which would also lower ...
... are developing new technology to create individualised brain maps ... accuracy of brain surgery. , Currently researchers and ... that are based on a small number of individuals, ... differences that can occur between people,s brains. , The ...
... Jersey Hospital, RIDGEWOOD, N.J., June 16 Ridgewood resident,David ... historic charitable contribution to The Valley Hospital in,Ridgewood, NJ. The ... its main campus, is thought to be the largest single ... gift to Valley because I want my giving to do ...
Cached Medicine News:Health News:Flavoring Food May Promote Weight Loss 2Health News:Flavoring Food May Promote Weight Loss 3Health News:New possibilities for breast cancer treatment on the horizon 2Health News:Personalizing medicine: New research shows potential of targeted therapies for cancer 2Health News:PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer 2Health News:Developing unique brain maps to assist surgery and research 2Health News:The Valley Hospital in Ridgewood, NJ, Announces Historic $30 Million Gift 2
... is a major upgrade of ... important physical and software changes ... and increase efficiency. The ACS:180 ... ACS:180. The productivity of the ...
... of Platelet aggregometers allows to choose ... needs. Single, dual and four sample ... outputs or digital computer outputs. In ... which measure platelet aggregation in platelet-rich-plasma ...
... four channel Platelet Aggregation Profiler with three ... (Ristocetin cofactor), platelet aggregation and leukocyte aggregation. ... the evaluation and confirmation of Heparin Induced ... to be run simultaneously and independently. Select ...
... a four channel platelet aggregation profiler with ... von Willebrand assay (Ristocetin cofactor), platelet aggregation ... be used for the evaluation and confirmation ... allow four tests to be run simultaneously ...
Medicine Products: